JP2011502517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502517A5 JP2011502517A5 JP2010533279A JP2010533279A JP2011502517A5 JP 2011502517 A5 JP2011502517 A5 JP 2011502517A5 JP 2010533279 A JP2010533279 A JP 2010533279A JP 2010533279 A JP2010533279 A JP 2010533279A JP 2011502517 A5 JP2011502517 A5 JP 2011502517A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- acid sequence
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 11
- 206010009944 Colon cancer Diseases 0.000 claims 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 9
- 201000002528 pancreatic cancer Diseases 0.000 claims 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 108010039491 Ricin Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 230000006820 DNA synthesis Effects 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010064785 Phospholipases Proteins 0.000 claims 1
- 102000015439 Phospholipases Human genes 0.000 claims 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 claims 1
- 230000006819 RNA synthesis Effects 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 230000003302 anti-idiotype Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229960004857 mitomycin Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 108700028325 pokeweed antiviral Proteins 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 1
- 229960004355 vindesine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99625507P | 2007-11-08 | 2007-11-08 | |
| US60/996,255 | 2007-11-08 | ||
| PCT/US2008/082821 WO2009062050A2 (en) | 2007-11-08 | 2008-11-07 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015043282A Division JP2015172045A (ja) | 2007-11-08 | 2015-03-05 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011502517A JP2011502517A (ja) | 2011-01-27 |
| JP2011502517A5 true JP2011502517A5 (enExample) | 2011-04-21 |
| JP5710978B2 JP5710978B2 (ja) | 2015-04-30 |
Family
ID=40626453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533279A Active JP5710978B2 (ja) | 2007-11-08 | 2008-11-07 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
| JP2015043282A Withdrawn JP2015172045A (ja) | 2007-11-08 | 2015-03-05 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
| JP2017022169A Withdrawn JP2017123851A (ja) | 2007-11-08 | 2017-02-09 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015043282A Withdrawn JP2015172045A (ja) | 2007-11-08 | 2015-03-05 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
| JP2017022169A Withdrawn JP2017123851A (ja) | 2007-11-08 | 2017-02-09 | 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原 |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US7829678B2 (enExample) |
| EP (2) | EP2217625B1 (enExample) |
| JP (3) | JP5710978B2 (enExample) |
| CN (1) | CN101854946B (enExample) |
| AU (1) | AU2008323811B8 (enExample) |
| CA (1) | CA2700197C (enExample) |
| ES (1) | ES2883176T3 (enExample) |
| MX (1) | MX2010004910A (enExample) |
| WO (1) | WO2009062050A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| DK2170384T3 (en) | 2007-07-02 | 2016-07-25 | Etubics Corp | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination |
| US20110256142A1 (en) * | 2007-09-06 | 2011-10-20 | Genmab A/S | Novel methods and antibodies for treating cancer |
| EP2217625B1 (en) | 2007-11-08 | 2021-08-04 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP2486052A4 (en) * | 2009-10-09 | 2013-05-01 | Merck Sharp & Dohme | GENERATION, LABELING AND USE OF ANTI-HER3 ANTIBODIES |
| EP3327035A1 (en) | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
| AR084141A1 (es) * | 2010-11-19 | 2013-04-24 | Imai Toshio | Anticuerpos neutralizadores anti-ccl20 |
| US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014106176A1 (en) | 2012-12-28 | 2014-07-03 | Precision Biologics, Inc. | Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer |
| US11279768B1 (en) | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
| EP3383430A4 (en) * | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| CA3007022A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-gitr antibodies and methods of use thereof |
| JP2018047144A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047145A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047147A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018047146A (ja) * | 2016-09-23 | 2018-03-29 | 株式会社三共 | スロットマシン |
| JP2018061577A (ja) * | 2016-10-11 | 2018-04-19 | 株式会社三共 | スロットマシン |
| US20190285635A1 (en) * | 2016-12-09 | 2019-09-19 | Shenzhen Senboll Biotechnology Co., Ltd. | Cnpy2 isoform 2 and the use thereof as molecular marker for colorectal cancer |
| CA3058790A1 (en) | 2017-04-24 | 2018-11-01 | Memorial Sloan Kettering Cancer Center | Anti-cd33 antibody agents |
| US12037410B2 (en) * | 2018-02-13 | 2024-07-16 | Precision Biologics, Inc. | Methods and compositions for targeting Treg cells |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| WO2022081443A2 (en) * | 2020-10-12 | 2022-04-21 | Memorial Sloan Kettering Cancer Center | Anti-psma antibodies and uses thereof |
| JP2024540374A (ja) * | 2021-11-05 | 2024-10-31 | アメリカン ダイアグノスティックス アンド セラピー, エルエルシー (エーディーエックスアールエックス) | がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US6190640B1 (en) * | 1985-04-19 | 2001-02-20 | Ludwig Institute For Cancer Research | Method for treating neoplasia using humanized antibodies which bind to antigen A33 |
| US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
| US5431897A (en) * | 1985-04-19 | 1995-07-11 | Sloan-Kettering Institute For Cancer Research | Method of imaging colorectal carcinoma lesion and composition for use therein |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| US5688657A (en) * | 1988-03-31 | 1997-11-18 | International Bio-Immune Systems, Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| USRE39760E1 (en) * | 1988-03-31 | 2007-08-07 | International Bio-Immune Systems Inc. | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor |
| AT393137B (de) | 1988-10-14 | 1991-08-26 | Biomay Biotech Prod | Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US6307026B1 (en) * | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| WO1996020219A2 (en) * | 1994-12-28 | 1996-07-04 | University Of Kentucky | Murine monoclonal anti-idiotype antibody 3h1 |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
| US5712369A (en) * | 1995-08-24 | 1998-01-27 | Ludwig Institute For Cancer Research | Isolated protein which binds to A33 antibody, and peptides corresponding to portions of the protein |
| US6417337B1 (en) * | 1996-10-31 | 2002-07-09 | The Dow Chemical Company | High affinity humanized anti-CEA monoclonal antibodies |
| ES2258817T3 (es) * | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| AU748973B2 (en) | 1997-07-17 | 2002-06-13 | Baxter Healthcare Sa | Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide |
| ES2279580T3 (es) | 1997-09-15 | 2007-08-16 | Genetic Immunity, Llc | Composiciones para administrar genes a celulas de la piel que presentan antigenos. |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US20030167531A1 (en) | 1998-07-10 | 2003-09-04 | Russell Douglas A. | Expression and purification of bioactive, authentic polypeptides from plants |
| US6512162B2 (en) | 1998-07-10 | 2003-01-28 | Calgene Llc | Expression of eukaryotic peptides in plant plastids |
| US6887464B1 (en) | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
| US6431897B1 (en) | 1999-10-06 | 2002-08-13 | Japan Aviation Electroncis Industry Limited | Connector having a rotary actuator engaged with a contact in a direction parallel to a sheet-like object connected to the connector |
| WO2001029242A2 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| US6846488B2 (en) | 2000-04-03 | 2005-01-25 | The Uab Research Foundation | Chimeric antigen-enterotoxin mucosal immunogens |
| US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| KR100419555B1 (ko) | 2000-05-29 | 2004-02-19 | 주식회사유한양행 | 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자 |
| US6680033B2 (en) | 2000-07-25 | 2004-01-20 | Asahi Environmental System Ltd. | Composite deodorization system and ion deodorization system |
| US6824989B1 (en) | 2000-09-01 | 2004-11-30 | Upstate Biotechnology, Inc. | Recombinant monoclonal antibody to phosphotyrosine-containing proteins |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| US6652853B2 (en) | 2001-03-08 | 2003-11-25 | Ludwig Institute For Cancer Research | Method for treating cancer using A33 specific antibodies and chemotherapeutic agents |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| WO2003016909A1 (en) * | 2001-08-16 | 2003-02-27 | Ludwig Institute For Cancer Research | Method for determining protein component in a biological sample |
| JPWO2003102183A1 (ja) * | 2002-06-03 | 2005-09-29 | 株式会社ディナベック研究所 | 抗体をコードするパラミクソウイルスベクターおよびその利用 |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| WO2005041747A2 (en) * | 2003-06-03 | 2005-05-12 | The Trustees Of The University Of Pennsylvania | Stealthy nano agents |
| CN1303105C (zh) * | 2003-12-08 | 2007-03-07 | 陈志南 | 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用 |
| US20060040027A1 (en) * | 2004-08-17 | 2006-02-23 | Kraft Foods Holdings, Inc. | Process for manufacture of grated cheese and uses thereof |
| TW200616662A (en) | 2004-09-10 | 2006-06-01 | Wyeth Corp | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| MY161894A (en) | 2006-09-08 | 2017-05-15 | Abbvie Bahamas Ltd | Interleukin-13 binding proteins |
| EP2217625B1 (en) * | 2007-11-08 | 2021-08-04 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP3327035A1 (en) * | 2010-06-22 | 2018-05-30 | Precision Biologics Inc. | Colon and pancreas cancer specific antigens and antibodies |
| US11279768B1 (en) * | 2015-04-03 | 2022-03-22 | Precision Biologics, Inc. | Anti-cancer antibodies, combination therapies, and uses thereof |
-
2008
- 2008-11-07 EP EP08846429.2A patent/EP2217625B1/en active Active
- 2008-11-07 WO PCT/US2008/082821 patent/WO2009062050A2/en not_active Ceased
- 2008-11-07 US US12/266,889 patent/US7829678B2/en active Active
- 2008-11-07 MX MX2010004910A patent/MX2010004910A/es active IP Right Grant
- 2008-11-07 CA CA2700197A patent/CA2700197C/en active Active
- 2008-11-07 CN CN2008801154194A patent/CN101854946B/zh active Active
- 2008-11-07 EP EP21177990.5A patent/EP3967712B1/en active Active
- 2008-11-07 JP JP2010533279A patent/JP5710978B2/ja active Active
- 2008-11-07 ES ES08846429T patent/ES2883176T3/es active Active
- 2008-11-07 AU AU2008323811A patent/AU2008323811B8/en active Active
-
2010
- 2010-08-19 US US12/859,526 patent/US8524456B2/en active Active
-
2011
- 2011-01-24 US US13/012,706 patent/US8802090B2/en active Active
-
2014
- 2014-06-19 US US14/308,851 patent/US9371375B2/en active Active
-
2015
- 2015-03-05 JP JP2015043282A patent/JP2015172045A/ja not_active Withdrawn
-
2016
- 2016-05-19 US US15/158,638 patent/US10023650B2/en active Active
-
2017
- 2017-02-09 JP JP2017022169A patent/JP2017123851A/ja not_active Withdrawn
-
2018
- 2018-06-15 US US16/009,497 patent/US20180346594A1/en not_active Abandoned
-
2020
- 2020-02-20 US US16/796,572 patent/US11401341B2/en active Active
-
2022
- 2022-06-24 US US17/848,694 patent/US11952429B2/en active Active
-
2024
- 2024-04-05 US US18/628,200 patent/US12344676B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502517A5 (enExample) | ||
| JP2015172045A5 (enExample) | ||
| JP2008538289A5 (enExample) | ||
| US12453780B2 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use | |
| Fukukawa et al. | Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10 | |
| RU2006105339A (ru) | Rg1 антитела и их применение | |
| EP2888282B1 (en) | Mesothelin domain-specific monoclonal antibodies and use thereof | |
| JP4898120B2 (ja) | Gpr64に対する抗体とその利用法 | |
| AU2004247270B2 (en) | Anti-CD74 immunoconjugates and methods | |
| JP2010510809A5 (enExample) | ||
| JP2010518847A5 (enExample) | ||
| JP2010537671A5 (enExample) | ||
| US9738726B2 (en) | HER2-specific monoclonal antibodies and conjugates thereof | |
| JP2008541711A5 (enExample) | ||
| JP2013512920A5 (enExample) | ||
| JP2008532523A5 (enExample) | ||
| JP2015510761A5 (enExample) | ||
| Hosseindokht et al. | Nanobodies: A tool to open new horizons in diagnosis and treatment of prostate cancer | |
| JP2020534830A5 (enExample) | ||
| RU2013120483A (ru) | Специфические к опухоли антитела и их применение | |
| WO2017023780A1 (en) | Antibody-drug conjugates for targeting cd56-positive tumors | |
| Shabaneh et al. | Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity | |
| WO2016022939A1 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
| JP2011509079A5 (enExample) | ||
| JP2007516232A5 (enExample) |